CoChat

Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?

Fang, Fang, Wang, Zuowei, Wu, Renrong, Calabrese, Joseph R., Gao, Keming · 2017 · Expert Review of Neurotherapeutics

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Antipsychotic-induced weight gain (WG) and metabolic abnormalities are major concerns. This review was untaken to answer if there is a weight-neutral second-generation antipsychotic for bipolar disorder (BPD). Areas covered: English-language literature in MEDLINE was searched with the keywords of antipsychotic/second-generation antipsychotic or generic/brand name of second-generation antipsychotic, and BPD/mania/depression or bipolar maintenance, and safety/tolerability or WG/weight increase, and randomized, placebo-controlled trial. Difference between an antipsychotic monotherapy and placebo in absolute weight gain (AWG) and/or ≥ 7% (WG in three phases of BPD was compared based on the data from original publications. The number needed to treat to harm was used for the comparison of ≥ 7% WG. Among antipsychotics with short-term (mania and/or bipolar depression) and long-term (maintenance) studies, olanzapine, asenapine, quetiapine, risperidone had significant WG compared to placebo in both short-term and long-term trials. Aripiprazole did not cause significant WG compared to placebo in short-term studies, but caused significant WG in long-term studies. Paliperidone-ER-induced WG was significant in a mania study as measured with AWG, and ziprasidone caused significant WG in a mania study measured with ≥ 7% WG. Expert commentary: These data suggest that it is unlikely there is a weight-neutral second-generation antipsychotic in BPD.

Overview

Integrity signals

Registry

Crossref · 10.1080/14737175.2016.1276284

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 67 references

Research works printed but not linked: 3

  1. Lipkovich I, 2009, Psychopharmacol Bull, 42, 23
  2. Gao K, Milestones in drug therapy series (M Parnham, J Bruinvels, series eds), bipolar depression: molecular neurobiology, clinical diagnosis, and pharmacotherapy
  3. Gao K, 2015, Neurosci, 31, 572

Cited by

See all 18

Metadata

Authors
Fang, F., Wang, Z., Wu, R., Calabrese, J. R., & Gao, K.
Affiliations
  • Shanghai Mental Health Center (CN)
  • Central South University (CN)
  • University Hospitals of Cleveland (US)
Corresponding author
  • Wang, Zuowei
  • Gao, Keming
Venue
Expert Review of Neurotherapeutics
Published
2017-01-02
Volume
17
Issue
4
Pages
407-418
ISSN
  • 1473-7175 (ISSN-L)
  • 1744-8360
OpenAlex
W2564477552
Cited by
18
References
67
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 1
FWCI
0.52
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Neurotherapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81301159)
  • Shanghai Key Medicine Specialties Program (ZK2012A12)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
bipolar disorder, atypical antipsychotics, antipsychotic-induced weight gain, aripiprazole, olanzapine, asenapine, quetiapine, risperidone, ziprasidone, metabolic side effects, mania, bipolar depression
MeSH terms
Olanzapine, Benzodiazepines, Bipolar Disorder, Humans, Antipsychotic Agents, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? https://app.cochat.ai/papers/10.1080/14737175.2016.1276284
The paper
Fang, F., Wang, Z., Wu, R., Calabrese, J. R., & Gao, K. (2017). Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2016.1276284

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.